Daewon Pharmaceutical's P-CAB new drug 'Fadoprazan' succeeds in Phase 3 trial; plans to file for product approval within the year
Predicted impact: Medium
Phase 3 success and approval filing plan are meaningful but already covered.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.